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Dihydrofolate reductase has been purified about 
1,000 fold v/ith an overall yield of Sf» from hog thymus 
glands. The purification procedure includes addition 
of protamine sulfate, ammonium sulfate precipitation, 
Sephadex G-lOO filtration, affinity chromatography on 
methotrexate-Sepharose and Sephadex G-25 filtration.
The purified enzyme existed as a single electrophoretic 
form and with a molecular weight 19,600 t 000 as 
estimated by Sephadex G-lOO filtration.
The catalytic activity of the hog thymus reductase 
was enhanced by chaotropic agents, such as salts and 
urea, but was inhibited by p-chloromercuribenzoate over 
the range 5 x 10~^ to 1 x 10”^ M. Double pH optima, 
one between pH 5.0 and 5-5 and another near pH 7.5 were 
observed. The presence of salts changed the pH-activity 
profile. The degree of inhibition of hog thymus reductase 
by methotrexate was dependent upon the pH. Binding of 
methotrexate to the enzyme was reversible.
The enzyme reaction follows a sequential mechanism. 
Competitive inhibition was observed for NADP with res­
pect to NADPH, whereas noncompetitive inhibition was 
obtained for NADP with respect to dihydrofolate. Some 
kinetic constants were also determined.
iii
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CHAPTER I 
INTRODUCTION
Background
In the last twenty years, our knowledge of the action 
of the vitamin folic acid at the molecular level has 
expanded greatly. Coenzyme derivatives of this vitamin 
play an important role in various one-carbon transfer 
reactions, such as amino acid metabolism, methyl group 
biosynthesis and purine-pyrimidine base synthesis. These 
studies on the function of folate coenzymes, carried out 
in numerous laboratories, have been reviewed by Blakley
(1) and by Rader and Huennekens (2), Parallel studies 
concerned with the biosynthesis of tetrahydrofdie acid, 
the coenz^nne form of folic acid, indicated that synthesis 
of the coenzyme may be the probable target site for the 
clinically useful antifolate drugs. Also, evidence has 
accumulated to indicate that a defect in tetrahydrofdate 
biosynthesis might constitute one of the means whereby 
the malignant cell proceeds to autonomous uncontrolled 
replication (3). Therefore, interest in folate metabolism 
has remained at a high level for the biochemist, the 
geneticist and the clinician.
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The structure of folic acid (pteroylglutamic acid) 
as shown below, consists of three portions (1) a substi­
tuted pterin, (2) p-aminobenzoic acid, and (3) glutamic 
acid. Naturally-occurring folate derivatives differ from 
each other in regard to the number of glutamate residues 
present in the molecule, the state of oxidation of the 
pteridine nucleus, and the type and site of attachment 
of one-carbon substituents,
COOH
ICHo 
I ^CH2
C — N — CH — COOH 
H
I_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 1 1 _ _ _ _ _ _ _ _ _ _ I I _ _ _ _ _ _ _ _ _ I
2-amino-4-hydroxy- p-aminobenzoic glutamic
6-methyl pterin acid acid
The antifolate drugs, aminopterin and amethopterin, are 
structurally related to folic acid as indicated below. 
These compounds have been used extensively in' the past in 
the treatment of certain malignancies such as leukemia 
and choriocarcinoma.
(pOOH 
CH2 
CHg
N — C H  COOH
H
aminopterin: NHg Rj>= H
amethopterin: NH^ R2"
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The conversion of folic acid to its coenzyme form,
5, 6, 7, 8-tetrahydrofolate (PĤ )̂ involves a two-stage 
reduction, with the intermediate formation of 7,8-dihydro- 
folate (PH^) (^.5)* Polic acid is reduced chemically to 
PHg by hydrosulfite or to by H^/Pd catalyst in glacial
acetic acid. Biosynthesis of is catalyzed by dihydro­
folate reductase (5. 6 , 7, 8-tetrahydrofolate : NADP** oxido- 
reductase, EC 1,5*1*3) in the presence of the coenzyme 
NADPH (or NADH to a less extent) (Reaction 1). Dihydro­
folate is the preferred substrate for the enzyme.
folic NADPH _ NADPH 5,6,7,8-acid ---------> 7,8-dihydrofolate  > tetrahydro-
folate
(Reaction 1)
Tetrahydrofolate subsequently functions as an intermediate 
carrier of a one-carbon group between donor and acceptor 
molecule. The one-carbon unit may exist at the oxidation 
level of formate, formaldehyde or methanol and is attached 
to the PĤ  ̂at either the N^ or N^^ position or bridged 
between them. The metabolic interrelationships of the 
various donors and acceptors of the one-carbon unit have 
been discussed in a number of review articles (1,2,5-9).
A reaction involving FHĵ  that has attracted considerable 
attention because of its role in the formation of DNA, is 
the synthesis of the methyl group of thymidylic acid.
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Although the coenzyme forms of are required in many
reactions, synthesis of thymidylic acid stands out as the 
most susceptible reaction to deprivation or antagonism of 
the coenzyme in rapidly dividing cells. Support for this 
belief comes from several studies reporting altered 
nucleic acid metabolism in tissue deficient in folic acid 
and vitamin . Increased ratios of RNA/DNA and uracil/ 
thymine have been demonstrated in bone marrow cells from 
patients v/ith megaloblastic anemia as compared with cells 
from normal patients (10,11). Moreover, a reduced DNA 
content has been observed in the intestine and liver cells 
of rats fed a diet containing the folic acid antagonists 
(12). Also, the sarcoma 180 tumors from mice (13,14) grown 
in cell culture in the presence of the antagonists had a 
reduced DNA content. Similar results have been shown in 
bacteria (15»l6), yeast cells (16), viruses (1?) and 
tissue culture cells (14,18,19). However, these altered 
metabolic states can be corrected by treatment with folic 
acid or vitamin . These findings, therefore point to 
an impaired synthesis of DNA as a major defect in folate 
deficiency. Should purine synthesis constitute the rate- 
limiting reaction, one would expect to see an inhibition 
of both KNA and DNA, since purines are common constituents 
of both molecules.
The synthesis of the methyl group of thymidylate 
appears to require higher substrate levels of FH^ than
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
any of the other one-carbon transfer reactions in cells 
undergoing rapid division. For example, the serine- 
glycine interconversion occurs at approximately the same 
rate in sprue patients severely deficient in FHĵ  as in 
normal patients (20). In contrast, thymidylic acid synthe­
sis is greatly diminished in patients deficient in FH^.
On the other hand. Totter and Best (21) have shown that 
formate incorporation into thymine is inhibited to a much 
greater degree than formate incorporation into purines in 
aminopterin-treated bone marrow cells in vitro.
Synthesis of thymidylic acid has been studied exten­
sively in a number of laboratories. The reaction involves 
the addition of a methyl group originating from the one- 
carbon pool through FHjî to the -position of deoxyuridylic 
acid to form thymidylic acid as indicated in Reaction 2 
below.
C IQdeoxyuridylic acid + N-̂ ,N -methylene FHĵ   >
thymidylic acid + FH^ (Reaction. 2)
In this enzyme-catalyzed reaction, FĤ  ̂not only acts as a 
carrier for the one-carbon unit but also furnishes the 
reducing equivalents necessary to convert the methylene to 
a methyl group. By using tritium labeled PH^, Friedkin (22), 
Wahba at (23), and Blakley at aT. (24) demonstrated
that the tritium was incorporated into the methyl group of 
thymidylic acid. The use of methylenetetrahydrofolate
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
specifically labeled with tritium indicated that it is 
the tritium at position 6 which is transferred without 
dilution (25).
Thus, for every molecule of thymidylic acid formed 
one molecule of FH^ is oxidized to FH^. Since FH^ itself 
is not active as a coenzyme, substrate levels of FH^ 
must be maintained in order for thymidylate synthesis to 
continue. This can be achieved either by a constant 
exogenous supply of FH^, or the regeneration of PH^ from 
FHg. Evidence has been presented to indicate that the FH^ 
formed during the thymidylate synthesis reaction is iden­
tical to the substrate of dihydrofolate reductase (26), 
and the enzymic regeneration of FĤ  ̂can be accomplished by 
this enzyme (2?,28). Therefore, an inoperative dihydro­
folate reductase would prevent cell replication by de­
creasing the production of FH^ and thus prevent the con­
tinuous generation of thymidylate. These metabolieally 
interdependent reactions have been termed the "thymidylate 
synthesis cycle" (29) (Figure 1).
Dihydrofolate reductase is the enzyme preferentially 
attacked by the antifolate drugs (30-35)» although the 
possible existence of other target site(s) has not been 
excluded. Therefore, thymidylate methyl formation would 
be expected to be inhibited to a greater extent than other 
FH^-mediated reactions in'which FH^ is not converted to FH^. 
A diagrammatic representation of the action of antifolates
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
ThymidylateDeoxyuridylate
thymidylate
synthetase
7,8-Dihydrofolate
N^,N -Methylene- 
tetrahydrofolate NADPH + H
dihydrofolate
reductase
NADP
Tetrahydrofolate
one carbon 
donor
Figure 1. Thymidylate Synthesis Cycle
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in proliferating tissues is shown in Figure 2. It empha­
sizes the increased thymidylate turnover in tissues with 
increased DNA synthesis, and the key role played by di­
hydrofolate reductase in this sequence. The consequences 
of dihydrofolate reductase inhibition by these antifolates 
is apparent.
General Aspects of Dihydrofolate Reductase
The distribution of dihydrofolate reductase in various 
tissues has been summarized by Blakley (1). Generally, the 
level of this enzyme in normal tissue is so low as to be 
barely detected. However, a highly increased level of enzyme 
has been detected from cells treated v/ith the folic acid 
antagonists or in the antifolate drug-resistant cells. 
Prearson e^ (36) reported a 2-6 fold increase in reduc­
tase -activity in mouse embryo cells infected with SV 40 and 
polyoma virus. Fischer (37), Hakala ejt (38) 1 and Misra
et al. (39) reported independently that marked increase of 
dihydrofolate reductase levels was found in mouse leukemia 
cells and sarcoma 180 cells which have become resistant to 
amethopterin. Antifolate drug-resistant strains of bacteria 
also showed higher activity in dihydrofolate reductase as 
compared with the sensitive strains (4o,4l).
Dihydrofolate reductase is present in traces, if at 
all, in leucocytes from normal patients or those with 
chronic lymphatic leukemia, but it is present in significant
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
antifolate
drugs
FHp
reductase
amino acid 
metabolismNADPH
FHp
reductase methyl group 
biosynthesisFolic Acid. FHNADPH
purine base 
synthesis
thymidylic acid
synthesis
VDNA synthesis
Vcell division
Figure 2. Action of antifolate drugs in proliferating 
tissues. Wavy lines indicate the site of inhibition.
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amount in leucocytes from patients with acute leukemia or 
with infectious mononucleosis or with chronic myelogenous 
leukemia (30,42-4^).
Dihydrofolate reductase has been isolated and par­
tially characterized from a variety of sources. Different 
molecular weights of this enzyme have been reported and 
can be grouped into three general categories;
(1) 15,000-22,000 range for the enzyme from bacterial 
sources (46-48), L1210 R cells (antifolate drug- 
resistant strain) (49), chicken liver (50)» Ehrlich 
ascites tumor (51)» and human leukocytes (52).
(2) 28,000-33,000 range for the enzyme from Streptococcus 
faecium (48), Escherichia coli phage (53)* and calf 
thymus (54).
(3) greater than 100,000 for the enzyme from Plasmodium 
berghei (55)* Diplococcus pneumonii (56), and several 
protozoa (57)*
The enzymes from bacterial sources within the first two 
categories show a single pH optimum, and can not be acti­
vated by chaotropes or by agents that react v/ith sulfhydryl 
groups. Reductases from the other sources have double pH 
optima and can be activated by chaotropes or mercurials 
under some circumstances. A wide variation is also seen in 
the values for the substrates, FH^ and NADPH.
Mention should also be made about the binding of the 
antifolate drugs to dihydrofolate reductase. Werkheiser (5 )̂
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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has indicated that the binding capacity of tissues for 
aminopterin is directly related to their dihydrofolate 
reductase content. The toxicity of the drug also correlated 
well with the degree of binding to the enzyme, and it was 
diminished by prior injection of folic acid, probably by 
interfering with the binding of aminopterin to the reduc­
tase. Contradictory results concerning the kinetics of 
inhibition of dihydrofolate reductase have been reported 
{30,32,3^,391 58-66). The type of kinetic behavior may 
depend upon the source of the reductase, the substrate used 
and the conditions, particularly the pH, used in the 
experiment. As summarized by Blakley (1), inhibition by 
amethopterin with folate as substrate is stoichiometric 
with all reductase preparations. With reductase from most 
animal sources, the inhibition has been described as 
stoichiometric or noncompetitive or both, especially at 
low pH. At higher pH, inhibition by the drug with FH^ as 
substrate is often intermediate between that expected of 
a stoichiometric inhibitor and tha.t exhibited by a compe­
titive inhibitor. Reductase from bacterial species shows 
similar variation' in the type of inhibition observed with 
amethopterin depending on the substrate, and the pH of the 
system.
Over the years a growing body of evidence has shown 
that there are species differences in the reductase's 
properties which may be important in determining the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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therapeutic usefulness of certain drugs. Therefore, the 
selective chemotherapeutic action against certain abnormal 
cells seems to be related to differential uptake of the 
drugs by cells and also to different structural and cata­
lytic properties of dihydrofolate reductase.
Although there have been many groups investigating 
dihydrofolate reductase, the most well known structural 
features of this enzyme were obtained from the bacterial 
and avian systems. During the last several years, investi­
gators have moved toward the mammalian system hoping to 
increase our understanding of the mechanism of dihydro­
folate reductase catalyzed reactions in higher organisms.
Thesis Objectives
Hog thymus was chosen as the source of dihydrofolate 
reductase in this study for the reasons that none of the 
reductase's properties were known and studies on thymidy­
late synthetase from this source v/ere in progress in this 
laboratory. Besides, thymus glands could be obtained 
readily from a local slaughter house when this study was 
begun.
The objectives of the present investigation were :
(1) purification of dihydrof olate reducta.se from hog 
thymus tissue,
(2) characterization of this enzyme and comparison with 
those from other sources, and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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(3) if possible, elucidation of the mechanism of this 
enzyme-catalyzed reaction.
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CHAPTER II 
MATERIALS AND METHODS
Materials
The following chemicals were obtained commercially» 
Folic acid, (d,1)L-tetrahydrofolic acid, protamine sulfate, 
3~ (4 , 5-d.imethylthiazoyl-2)-2, 5-diphenyltetrazolium bromide 
(MTT-tetrazolium), NADPH, NADP, 2-mercaptoethanol, and 
Trizma base (Tris) (Sigma); Sephadex G-lOO, G-25, and 
Sepharose 4b (Pharmacia)j ammonium sulfate (J.T. Baker 
Chemical Co.)? standard protein kit for molecular weight 
determination (Schwarz/Mann), Methotrexate was a gift from 
Dr. Larson in the Microbiology Department, University of 
Montana.
FHg was prepared from folic acid by chemical reduction 
v;ith hydrosulfite according to the method of Blakley (67,
68). The dried powder was stored frozen under vacuum in 
sealed vials. A solution of 2.0 x 10”  ̂M FH^ (^282~ 28,000 
M“"cra''̂ ) v/as prepared in O.05 M Tris buffer, pH 7.2, 
containing 0.01 M 2-mercaptoethanol. NADPH of 2.6 x 10”  ̂M 
was prepared in the same buffer but without mereaptoethanol.
Dialysis tubing (Union Carbide Corp.) was washed by 
heating at 60-70° C for one hour in 0.1 M 2-mercaptoethanol, 
followed by repeated rinsing with distilled water, and was
ostored in distilled water at 4 C.
14
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Methods
Standard Spectrophotoinetric Assay. Dihydrof olate 
reductase was measured according to the spectrophotometric 
method of Osborn £t (64), The reaction rate was
followed by measuring the decrease in absorbance at ])40 nm 
by using a Gilford multisample absorbance recorder (set at 
0-0.560 full scale) equipped with a constant temperature
Owater bath at 37 C. The following components were added 
to a 1.0 cm cuvette I 0.05 i»l of 2.6 x 10”  ̂M NADPH, enzyme 
and 0.05 M Tris buffer, pH ?,2. After a 5 minutes incuba­
tion period at 37°C, 0.05 ml of 2.0 x 10”  ̂M FH^ was added 
to initiate the reaction. The total volume of reaction 
mixture was 1.2 ml. FHg or NADPH v/as omitted from the 
appropriate blank. During reduction of dihydrofolate, both 
FHg and NADPH disappearance cause a decrease in absorption
at 340 nm ( ^4o,NADPH~ 6.2 x 10^ M cm , ^34o,FH^~
3 — 1 — X 'X 10-̂  M” cm~ ) . Therefore the observed absorption change
was corrected for disappearance of NADPH alone.
Modified Spectrophotometric Assay. The kinetic 
studies were done with the Cary I5 recording spectrophoto­
meter, The reaction rate was measured by following the 
decrease in absorbance at ŷ O nm for 5 minutes at room 
temperature against the appropriate blank. The reaction 
mixture (total volume 30*20 ml) contained NADPH, enzyme, 
the assay buffer, and FH^ in a cylindrical cuvette with
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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a 10.0 cm light path. In the product inhibition study, 
different levels of NADP or were also included. Either
FHg or NADPH was added to initiate the reaction. One unit 
of enzyme activity is defined as the amount required to 
reduce 1 Aimole of per minute under the assay conditions,
Specific activity is expressed as units of enzyme per mg 
of protein. Protein was determined by the Lowry method 
(69), using bovine serum albumin as the standard.
Preparation of the Chromatographic Materials.
Sephadex G-lOO and G-25 was allowed to swell for 24 hours 
in 0.05 M potassium phosphate buffer, pH 7.5» then washed 
wi^h an additional 0.5 to 1.0 liter of buffer. After each 
use the Sephadex was removed from the column, washed 
extensively with water, and reequilibrated with phosphate 
buffer. When not in use for an extended period of time, 
the gel was stored in phosphate buffer containing 0.02 fa 
sodium azide.
Preparation of Substituted Agarose. The following 
procedure was the modified method of Whiteley _et (70).
Sepharose 4b (wet-volume 25 ml) was washed with water to 
remove sodium azide. The washed Sepharose was activated 
at room temperature by the addition of 25 ml of cyanogen 
bromide (100 mg/ml). The mixture was adjusted to pH 11.0 
with 4 N NaOH and maintained at this pH for 10 minutes.
The suspension was filtered rapidly on a Buchner funnel
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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and the residue was washed with 250 ml of ice-cold 0.1 M 
NaHCO^, pH 9.0. The gel was resuspended in cold 0.1 M 
NaHGO^, pH 9.0» and 5 ml of 1.0 M 1,6-hexanediamine was 
added with stirring to the suspension. The washing and 
the addition of the diamine was completed in less than 90 
seconds. After mixing gently for 24 hours at 4° G, the 
suspension was filtered and the residue was washed thor­
oughly, first with buffer and then with water. The result­
ing io-aminohexyl derivative of Sepharose was resuspended 
in 25 ml of water and to it was added 58 mg of methotrexate 
dissolved in 5 ml of H^O and 500 mg of 1-ethyl-3-(3-di- 
methylaminopropyl) carbodilmide at pH 6.5. The mixture was 
stirred for 3 days at room temperature to ensure complete 
coupling of the methotrexate to the insoluble modified 
Sepharose. The bright yellow gel was recovered by filtration 
and v/ashed successively with water, 0.1 N NaHGO^, water,
0.1 N NaOH, water, 0.1 N HGl and finally with water until 
the resulting filtrates were colorless. The final product 
was stored as an aqueous suspension in the cold and pro­
tected from light. The amount of methotrexate coupled with 
the Sepharose was determined spectrophotometrieally by 
subtracting the amount recovered in the combined washings 
from that initially present. About 1 rag of methotrexate 
(2.2 X 10"^ mole) v/as found to be coupled per ml of wet 
Sepharose.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Purification of Dihydrofolate Reductase from Hog 
Thymus. Hog thymus tissue v/as purchased from John R.
Daily Co., Missoula, Montana. The tissue was placed in ice 
as soon as possible after the animals had been slaughtered. 
Centrifugations were performed in a Sorvall refrigerated 
centrifuge, Model RC2-B, using the GSA rotor at 12,000 rpm 
(23,300 X g). In the chromatographic steps, fractions were 
collected automatically by a Gilson Escargot fraction 
collector. Unless stated otherwise, all purification steps 
were performed at 0-5°C.
Step 1. Homogenate. Fresh hog thymus glands (about 900 
gi-Tims) were trimmed, cut into small pieces, and homogenized 
in three volumes of O.05 M phosphate buffer, pH 7.5, con­
taining 0.001 M EDTA and 0.15 M KGl in a waring blender 
for a total of 75 seconds. The homogenate was centrifuged 
for 40 minutes and the pellet was discarded.
Step 2. Protamine sulfate precipitation. About 0.1 volume 
of 5 ^ protamine sulfate was added to the supernatant fluid 
from Step 1. The mixture was stirred for an additional 15 
minutes, centrifuged, and the pellet was discarded.
Step 3. Ammonium sulfate precipitation. Solid ammonium 
sulfate v/as added slowly with stirring to the protamine 
sulfate supernatant to 65 % saturation (430 g/liter). After 
the ammonium sulfate had dissolved, the suspension was 
stirred for an additional I5 minutes, adjusted to pH 7.0,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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centrifuged for ^5 minutes, and the pellet was again 
discarded. The supernatant fluid was brought to 90 fo 
saturation with solid ammonium sulfate (190 g/liter), 
mixed for 15 minutes, adjusted to pH 7.0, and centri­
fuged for 45 minutes. The pellet was dissolved in a 
minimum amount of 0.05 M phosphate buffer, pH 7-5. The 
65-90 % ammonium sulfate fraction was dialyzed for two 
and half hours against two 2-liter changes of 0.05 M 
phosphate buffer, pH 7.5. Any insoluble material was 
removed by centrifugation for 20 minutes.
Step 4. Gel filtration through Sephadex G-100.
Sephadex G-100, preequilibrated with O.05 M phosphate 
buffer, pH 7.5, was added to a 5 cm column to a height 
of 54 cm, and washed with 500 ml of buffer. Approximately 
one-half of the dialyzed 65-90 fo ammonium sulfate fraction 
was added to the column at one time and eluted with 
phosphate buffer. Flow rate was 40-60 ml/hr and fractions 
of 8 ml per tube were collected. Protein fractions con­
taining reductase activity (tubes 6I-76 in Figure 3) from 
the tv;o column operations were combined together.
Step 5. Affinity chromatography. The pooled enzyme 
fraction (about 3OO ml) from Step 4 was applied to a 2 x 
16 cm column of methotrexate-Sepharose (bed volume 55 ml) 
preequilibrated with O.O5 M phosphate buffer, pH 7.5* Flow 
rate was 30-40 ml/hr, and fractions of 6 ml were collected.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Figure 3. Filtration of FH^ reductase, post ammonium 
sulfate fraction, on Sephadex G-100. Conditions des­
cribed in text.
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Nonadsorbed protein was washed from the column with an addi­
tional 50 ml of the starting buffer. The column was then 
washed with 100 ml of 0.10 M phosphate buffer, pH 8.5, 
followed by 200 ml of the same buffer containing about 
10”^ M PH2 to facilitate elution of dihydrofolate reduc­
tase. The pooled enzyme fraction (tubes 64-69 in Figure 4) 
was then concentrated in an Amicon ultrafiltration appa­
ratus equipped with a PM-10 membrane, or by overlaying 
with sucrose. If the absence of FHg was not absolutely 
necessary in subsequent studies, this sample was kept 
frozen at pH 6.5 until further use.
Step 6. Gel filtration through Sephadex G-25. PH^ was 
removed from the concentrated enzyme fraction from Step 5 
by filtration through a 2.5 x 28 cm Sephadex G-25 column 
preequilibrated with 0.10 M phosphate buffer, pH 8.5*
(flow rate 20 ml/hr); fractions of 1.5 ml were collected.
The fractions containing enzyme activity (tubes 20-34 in 
Figure 5) were pooled, and concentrated by either pressure 
ultrafiltration or by sucrose concentration as described 
above, and stored in the freezer for further use.
Microzone Electrophoresis. Dihydrofolate reductase 
was applied to a cellulose acetate membrane and subjected 
to electrophoresis at 450 volts for 50 minutes in a 
Beckman Microzone Cell, Model R-101. The buffer was 0.I3 M 
Tris-O.071 M borate, pH 8,6, containing 3 x lO”  ̂M EDTA,
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Figure 4. Affinity chromatography of FH^ reductase, post 
G-100 fraction, through methotrexate-Sepharose. Conditions 
described in text. Buffer was changed to 0.1 M phosphate, 
pH 8.5 at arrow A. Enzyme was eluted with the above buffer
containing 10-4 M FHg at arrow B.
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Figure 5- Filtration of FH^ reductase, post methotrexate- 
Sepharose fraction, through Sephadex G-25. Conditions 
described in text.
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Protein was located with 0.2 ^ Ponceau-S stain (Beckman 
fixative dye solution), and the cellulose acetate membrane 
was destained with 5 ^ acetic acid. Enzyme activity was 
detected by the method of Gunlack at (71) as modified
by Mell et â . (?2). Special Agar-Noble (135 mg) was 
dissolved with heating in 5 ml of 0.1 M Tris buffer, pH 
7.5* When the agar had cooled to about 70° G, the f ollov/ing 
substances were added; MTT-tétrazolium (2.5 mg/2.5 ml of 
0,10 M Tris, pH 7.5) , NiADFH (2.5 mg/o. 5 ml of the same 
buffer), and mercaptoethanol-free FHg (1.5 mg/O.5 ml of 
the same buffer). The resulting mixture was poured quickly 
into a shallow, rectsngular tray end allowed to solidify=
The cellulose acetate membrane after electrophoresis, was 
placed on the agar and allowed to stand at 37°G in an 
incubator. Appearance of violet spots indicated existence 
of dihydrofolate reductase. An agar plate containing 5 x 
10“  ̂M methotrexate in addition to the other above reactants 
was used to confirm the presence of dihydrofolate reductase.
Molecular Weight Determination. The molecular v/eight 
of dihydrofolate reductase was estimated by filtration 
through a 2 X 88 cm column of Sephadex G-100 (bed volume 
I50-I60 ml, flow rate 18 ml/hr) by a modification of the 
method of Whitaker (73)* The column v/as equilibrated with 
0.05 M Tris buffer, pH 8.4, and calibrated by adding 
separately six standard protein solutions (2-5 mg protein/
1 ml of the above buffer). Fractions of 1.5 mil were
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collected. Elution volume for a given protein was calcu­
lated from the maximal point of its elution peak. The 
void volume of the column was determined by measuring 
the elution volume of Apo-Ferritin, an amorphous protein 
with molecular weight 480,000 daltons.
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CHAPTER II 
RESULTS
Assays of Enzyme Activity
The spectrophotometric assay for dihydrofolate 
reductase activity was used throughout this investigation. 
Relatively large blank corrections were observed in the 
early stages of purification, i.e. the tissue homogenate 
and post protamine sulfate fraction. These early enzyme 
fractions should be as free as possible of particulate 
material to prevent interference in the assay mixture. 
Unless stated otherwise, the spectrophotometric assay 
was performed at 37°G since the enzyme was present in 
small amounts in the tissue.
Purification Procedure
About 15 enzyme preparations were made in the course 
of this study. Typical results of the purification proce­
dure are summarized in Table 1. The enzyme was purified 
approximately 1,000 fold with an overall yield of 5 The 
protein value for the post MTX-Sepharose and Sephadex G-25 
fraction is not available due to the low concentration of 
protein and the presence of FH^ and mereaptoethanol in the 
Sepharose fraction which interfered v/ith the Lowry assay. 
Considerable loss of enzyme activity was observed following
26
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TABLE 1
PURIFICATION OF DIHYDROFOLATE REDUCTASE
FROM !391 g OF HOG THYMUS GLANDS
Fraction
(ml)
Reductase
Activity
(units)
Specific Protein Activity
(mg) (units/mg)
Recovery
(̂ )
Tissue
Homogenate 1630 51 68,000 0.00075 100
Protamine
Sulfate 1620 39 39,000 0.0010 76
Dialyzed 65- 
90fo Ammonium 
Sulfate
90 24 6,300 0.0038 47
Sephadex G-100 316 17 1,900 0.0089 33
MTX-
Sepharose 344 13 26
Sephadex G-25 123 5.7 11
Concentration 
with Sucrose 23 2.5 3.3 0.76 5
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precipitation of protein with ammonium sulfate. Little or 
no enzyme activity was found in the 35-̂ 5 % ammonium sul­
fate fraction. About I3 % of the activity was not precipi­
tated from the solution by adjusting to 90 % ammonium 
sulfate which at 0-5°G represents a nearly saturated 
solution. Therefore, inherent instability of dihydrofolate 
reductase itself and incomplete precipitation with ammonium 
sulfate account for the low yield. The most striking in­
crease (abut 80 fold) in specific activity occurred fol­
lowing affinity chromatography on MTX-Sepharose.
In the earlier experiments, the Sephadex and Sepharose 
fractions were concentrated by pressure filtration, but 
significant loss of enzyme activity was observed. It was 
later found that concentration of the protein samples by 
the sucrose method resulted in improved recovery of enzyme 
activity.
In terms of stability of the hog thymus enzyme, 50 
of its activity was lost by storing at 4°C for one week at 
either pH 7*5 or pH 8.5. However, no significant loss of 
enzyme activity v/as found when it was kept frozen for 
several months. The addition of NADPH or EDTA to the enzyme 
solution did not help to stabilize the enzyme at 4°C.
Electrophoresis Results
Purity of the final enzyme fraction, as well as the 
possible presence of multiple forms of dihydrofolate
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reductase, was investigated by electrophoresis on cellu­
lose acetate. Unfortunately, the concentration of protein 
in the purified enzyme preparation was so dilute that no 
protein bands were visualized when the electrophoretogram 
was stained with Ponceau S dye. Thus, the protein hetero­
geneity of the sample is unknovm.
The purified hog thymus enzyme preparation showed a 
single form of dihydrofolate reductase on cellulose acetate, 
whereas reductase purified from chicken liver existed as 
multiple forms. As shown in the drawing below, the hog 
thymus enzyme moved faster than the minor fast-moving form 
of the chicken liver enzyme. No enzyme activity in either 
preparation was detected on the electrophoretogram v/ith 
5 X 10“^ M MTX present in the staining mixture.
chicken liver 
reductase
hog thymus 
reductase
origin
Molecular Weight
Dihydrofolate reductase from hog thymus has a molecular 
weight of 19,600 t 3,000 as determined by filtration'through
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Sephadex G-100 (Figure 6). The deviation range was derived 
by using the Equation for Confidence Interval for Single 
Additional Observation (7^). Thus, the enzyme from hog 
thymus tissues has a molecular weight similar to that 
reported for 1,1210 R and chicken liver enzyme (category 1,
p.10).
Effects of Chaotropic Agents and p-Chloromercuribenzoate
Some but not all dihydrofolate reductases are activated 
by chaotropic agents, i.e. salts and urea, and by certain 
organic mercurials which are known to alter the secondary 
or tertiary structure of proteins in aqueous solution. 
Potassium chloride and ammonium sulfate activated the hog 
thymus reductase as presented in Figure 7. Maximal acti­
vation was achieved at 0.7 M KOI and at 0.1 M (NHj^)2S0^.
The reductase was activated approximately 2.5 to 3 
fold by 3 M urea as shown in Figure 8. Higher concentrations 
of urea resulted in loss of enzyme activity.
The hog thymus enzyme was not activated by p-chloro- 
mercuribenzoate (pCMB) over the concentration range 10”^ 
to 10“^ M (Figure 9). At concentrations greater than 5 x 
10"^ M the mercurial inhibited enzyme activity. In contrast, 
the mercurial gives a 4 fold increase in enzyme activity for 
the dihydrofolate reductase purified from Ehrlich ascites 
cells (75»76) and chicken liver (77).
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Figure 6. Molecular weight estimation of FHg reductase 
on Sephadex G-100. Conditions described in text. To the 
column was added 2.5 ml of a post MTX-Sepharose enzyme 
fraction (0.24 units/ml, A2qq=1.480). Dashed line indi­
cates the value for FH^ reductase.
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Figure ?. Activation of FH^ reductase by potassium 
chloride (x) and ammonium sulfate (<=>), Standard 
spectrophotometric assay conditions were performed, 
except the assay buffer contained the indicated 
concentrations of KGl or (NH^)2S0^.
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Figure 8. Activation of FH^ reductase by urea. Urea was 
added to the standard assay to give the indicated con­
centration.
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Figure Inhibition of FHg reductase by p-chloromercuri- 
benzoate. Standard assay conditions, except pCIVlB was 
added to give the indicated concentrations and FHg was 
freshly prepared in the absence of mercaptoethanol.
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pH Optimum
The activity-pH profile of dihydrofolate reductase 
showed two optimal values, one between pH 5*0 and 5*5» 
and another near pH 7.5 as indicated in Figure 10. Enzyme 
activity was slightly higher at the alkaline pH optimum. 
More enzyme activity was observed in phosphate than in 
acetate buffer.
In the presence of KGl, the enzyme activity-pH profile 
(Figure 11) remained similar in the acid range to that 
observed in the absence of salt, whereas the pH optimum 
at 7*5 appeared to be shifted to 8.4. On the other hsind, 
in the presence of (NHj^)^SO^, the enzyme had relatively 
constant activities from pH 6.0 to 9.0.
Inhibition by Methotrexate
Hog thymus dihydrofolate reductase, like its counter­
part from other sources, is extremely sensitive to the anti­
folate drug methotrexate. As shown in Figure 12, at pH 7.2, 
a drug concentration of 10” M was sufficient to cause 
greater than 50 %  inhibition of enzyme activity. At pH 6.5 
and 8.4, the inhibition by the drug was about 30 %  and 20 fo 
respectively. Inhibition of reductase activity leveled off
at 80 % with concentrations of methotrexate greater than 
—  85 X 10“ M. Inability to achieve 100 fo inhibition has been 
observed also in lÆTX-resistant cells of mouse leukemia 
L4946 (78) and Diplococcus pneumonii (79).
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Figure 10. The pH optimum for FHg reductase. The Tris 
buffer in the standard spectrophotometric assay was 
replaced with the following buffers at the indicated 
pHi 0,05 M sodium acetate ( x ) ;  0.05 M potassium phos­
phate (o)î and 0.05 M Tris (*). The blank for results 
below pH 6.5 contained NADPH and FHg, but no enzyme to 
account for the acid degradation of coenzyme.
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Figure 11. Effect of KOI and (NH^) the pH optimum
of FHg reductase. Conditions were the same as for Figure
10, except in the presence of 0,64 M KOI (------) or
0.09 M (NH^)gSO^ (------).
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Figure 12. Inhibition of PHg reductase by methotrexate, 
Inhibition was measured at pH 6.5 (x); pH 7.2 (o); and 
pH 8.4 (A). Methotrexate present in the assay buffer 
was incubated with enzyme and NADPH for 5 minutes at 
37°C. FHg was added to the solution to initiate the 
reaction.
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Initial Velocity Studies
The reaction mechanism of dihydrofolate reductase 
was studied by using the kinetic analysis devised by 
Cleland (80). This approach involves measurement of the 
initial velocity of the reaction at varying concentrations 
of one substrate and at different fixed levels of the 
second substrate. A plot of reciprocal velocity versus 
reciprocal concentration of variable substrate gives a 
series of linear lines intersecting to the left of the 
vertical axis with a sequential mechanism» i.e. both 
substrates react with the enzyme before any product is 
released. If the initial velocity pattern is a series of 
parallel lines, a pingpong mechanism is suggested in 
which one substrate is bound to and one product is re­
leased from the enzyme prior to the addition of the
second substrate.
As shown in Figures 13 and l4, when the initial velo­
city data were plotted with NADPH or FH^ as the variable 
substrate, a family of nonparallel lines, consistent with 
a sequential mechanism, was obtained. If the slope and 
intercept in Figure 14 were then plotted against the 
reciprocal concentrations of NADPH, the changing fixed
substrate, the replots were linear. The Michaelis con­
stants and dissociation constant calculated from these 
data are presented in Table 2. Nonlinear replots were 
obtained in the case of FH^.
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Figure I3. Effect of FH^ on the initial velocity of 
FHg reductase with NADPH as the variable substrate.
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Figure 14, Effect of NADPH on the initial velocity of 
FHg reductase with FH2 as the variable substrate.
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TABLE 2
KINETIC CONSTANTS
Kinetic Constant Value(aim)
^NADPH 0.6
0.8
‘'i PHg 2.3
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Product Inhibition Studies
Since there are a number of possible sequential 
mechanisms (81), i.e. ordered, Theorell-Ghance, or rapid 
equilibrium type, product inhibition studies by both NADP 
and were carried out with respect to each substrate
to distinguish between these mechanisms. However, experi­
ments with FH^ as the product inhibitor were not success­
ful due to the instability of FHĵ  itself. Concentrations 
of mercaptoethanol greater than 0.1 M in the assay 
mixture might have overcome this difficulty; however, the 
small amount of purified enzyme and the lack of time did 
not allow me to repeat this portion of the study.
A pattern of competitive inhibition was obtained by 
the product NADP with respect to NADPH (Figure 15)* Non­
competitive inhibition was observed by NADP with respect 
to FHg (Figure 16), Replots of slope or intercept in 
Figures 15 and 16 versus concentrations of NADP resulted 
in a nonlinear relationship. Proper interpretation of the 
nonlinear replots requires further experimentation.
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Figure 15. Inhibition of FH^ reductase by NADP with NADPH 
as the variable substrate. (FHg] was fixed at 6.6 /uM.
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Figure 16. Inhibition of FHg reductase by NADP with FHg 
as the variable substrate, (nadph) was fixed at 12,9 yuM.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
CHAPTER IV 
DISCUSSION
Dihydrofolate reductase has been purified approximately 
1,000 fold from hog thymus glands. Affinity chromatography 
is the most effective step in the purification procedure.
This technique exploits the specific reversible interaction 
between ligand and biopolymer (82). The method (83,84) con­
sists of coupling covalently a spacer group, 1,6-hexane- 
diamine to agarose activated by cyanogen bromide. Metho­
trexate was coupled to the terminal amino group of the 
spacer compound via its carboxyl groups by means of a carbo- 
diimide condensation reaction. It has been shown that the 
coupled methotrexate retains its ability to bind to FH^ 
reductase (83). Thus, methotrexate covalently attached to 
the insoluble gel was able to adsorb the reductase from 
solution. Methotrexate interacts with the enzyme much less 
strongly at alkaline pH as presented earlier in Figure 12, 
therefore, the methotrexate-enzyme complex was dissociated 
by changing the pH of the buffer. FHg is included in the 
alkaline buffer to further promote dissociation of the enzyme- 
inhibitor complex. In the present study, about an 80 fold 
purification of the enzyme was achieved in this single step
(Table 1). A nearly 4,000 fold purification of FHg reductase
46
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was reported from rat skin by this technique (84).
Additional purification steps were explored, such as 
fractionation with ethano1-chloroform mixture and precipi­
tation of proteins and nucleic acids at pH 5*4, but none 
of these methods were found successful.
Specific activity of the purified hog thymus enzyme 
was similar to values reported for the reductase from some 
other animal sources (4,51,52,61,85.86). The presence of 
multiple forms of the reductase in purified hog thymus 
preparations could not be detected by electrophoresis on 
cellulose acetate. In contrast, the purified chicken liver 
enzyme (72) and that from L. casei R (4?) were reported to 
exist in several forms. The multiple forms were intercon- 
vertable depending on the amount of NADPH bound to the 
protein. The thymus enzyme migrated about one-third faster 
than the fastest moving enzyme form from chicken liver. 
Therefore, the hog thymus enzyme as compared with the chicken 
liver enzyme may differ in amino acid content, the number of 
amide groups, and hence the net charge existing in the protein 
molecule.
The molecular weight of the hog thymus enzyme is appro­
ximately 20,000, which falls into category 1 on page 10. The 
reductases in category 3 have a molecular weight greater 
than 10^. The possibility that they might be composed of 
subunits or associated with some other protein or nucleic 
acid awaits further investigation. Amino acid analyses
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have been reported for the chicken liver enzyme (87) and 
the enzyme from L. casei R (88) and L1210 R cells (89), 
but there is no evidence at present that any of the FHg 
reductases with low molecular weight achieve quaternary 
structure by utilizing the subunit-aggregating phenomenon. 
The hog thymus reductase consists probably of a single 
polypeptide chain based on its low molecular weight.
FHg reductase from hog thymus, like its counterpart 
from most animal tissues (90), was stimulated 2-3 fold by 
chaotropic agents. The activating agent is envisioned as 
inducing some type of conformational change in the protein 
(91). From the evidence that the activated enzymes are 
more susceptible to proteolytic digestion or to heat dé­
naturation (92), the transition is suggested likely that 
from a compact to an unfolded form.
p-Chloromercuribenzoate, a modifier of sulfhydryl 
groups, was shown to inhibit the hog thymus reductase in 
agreement with results reported for the calf thymus enzyme 
(6l) and that purified from S. faecalis R (34). FH^ re­
ductases from chicken liver and 11210 cells, both of which 
may be activated by pCMB, contain two cysteine residues 
per molecule (87). Enzyme purified from 1. casei R fails 
to be activated by pCMB and contains no cysteine residues 
(88). From these experiments, it is believed that pCMB 
reacts with the enzyme, probably via a protein sulfhydryl 
groups this effect may result in a change in the
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conformation of the enzyme leading to enhanced or dimi­
nished activity. Further investigation as to the possible 
involvement of sulfhydryl groups and the mechanism of 
mercurial action in hog thymus reductase appears to be 
necessary.
Hog thymus reductase, like others from animal tissues, 
showed double pH optima. Enzyme activity was slightly higher 
at the alkaline pH value which is similar to that observed 
for the human leukocytes enzyme (43»52). Chaotropic agents 
changed the pattern of the pH-profile as presented in Figure
11. In the studies of chicken liver enzyme, Kaufman e_t al. 
(50) reported a shift of the acid optimum from pH 4.0 to
4.5 with 2 M KOI present, whereas a single optimum was 
observed at pH 6.4 in the presence of 2 M urea (93).
Methotrexate is the most potent reductase inhibitor
thus far known. As shown in Figure 12, 5 0 ^  inhibition was
—  ftachieved with less than 10” M methotrexate at pH 7.2. 
Changing the pH decreased the percent inhibition by the 
folate antagonist. Werkheiser (58) introduced the techniques 
of titrating reductase with the drug which requires that 
enzyme and inhibitor combine irreversibly in a stoichio­
metric manner. Work from Bertino's laboratory (65) has 
shown that the degree of enzyme-inhibitor interaction 
depends upon the pH and the ionic environments at acid pH 
values the binding tends to be stoichiometric while at 
alkaline pH it becomes reversible.
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The reaction mechanism of PH^ reductase from hog thymus 
is sequential based on initial velocity studies. This finding 
is in agreement with studies on the enzyme from S. faecium 
(9^), L1210 cells (95) and E. coli (96). The estimated 
kinetic constants presented in Table 2 were obtained by 
fitting the data to the equation for a sequential mecha­
nism (81).
Product inhibition studies were performed in order to 
differentiate among the several possible sequential mecha­
nisms. Difficulties were encountered in some of these 
experiments due to the instability of FH^ and the small 
amount of purified enzyme. No data have been obtained with 
FHĵ  inhibition. A summary of the predicted and experimental 
inhibition patterns, together with those reported from other 
sources are listed in Table 3* As can be seen, significant 
differences in mechanism distinguish the enzyme from each 
other. Thus, minor differences at the active center or in the 
structure of the enzyme are suggested by the kinetic analysis. 
The type of sequential mechanism for hog thymus reductase 
can not be proposed yet due to the lack of information on 
FHjî inhibition.
Replots of slope or intercept in Figures 15 and l6 
versus concentrations of NADP appeared to be hyperbolic with 
NADPH as the variable substrate, and parabolic with FH2 as 
the variable substrate. A more detailed analysis of the 
nonlinear kinetic data by computer programmes proposed by
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TABLE 3
PATTERNS OF PRODUCT INHIBITION FOR FHg REDUCTASE
A. Predicted Patterns for Some Sequential Mechanisms'
Inhibition by 
NADP
Inhibition by 
FH,.
Mechanism
NADPH
varied FHpvaried
NADPH
varied ™8- .varied
Ordered, NADPH first^ C NC NC NC
Ordered, FHg first^ NC NC NC C
Random NC NC NC NC
Rapid equilibrium C C C C
The ore11-Chanc e^ NC C C NC
B, Experimental Patterns
S. faecium (89)
mutant enzyme C NC NC NC
wild type enzyme C NC? — —
L1210 murine lymphoma (90) c NC C C
E. coli enzyme (91) c UC? NC? NC C
Hog thymus enzyme c NC — -----
li At fixed nonsaturating concentrations of the second 
substrate.
21 NADPH reacted first and NADP released last 
3* FHg reacted first and FH^ released last 
4* FHg reacted first and NADP released last
The abbreviations used are *
C* competitive, NC» noncompetitive, UCi uncompetitive 
— % information not available 
?i uncertainty
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Cleland (97) is required to clarify the reaction mechanism.
The results of this investigation, as well as those 
from others, have illustrated that FH^ reductase from 
animal and bacterial sources differs with respect to its 
physical and chemical properties. The enzymes have been 
shown to differ in size, pH optimum, reaction mechanism, 
and sensitivity to chaotropic agents, mercurials, inhibitors. 
These differences, although small in nature, are the basis 
of a rational development of new chemotherapeutic agents 
capable of specially inhibiting the FH^ reductase in 
abnormal cells, while having little or no effect on the 
enzyme in normal cells.
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CHAPTER V 
SUMMARY
Dihydrofolate reductase has been purified about 1,000 
fold with an overall yield of 5 ^ from hog thymus glands. 
The purification procedure includes addition of protamine 
sulfate, ammonium sulfate precipitation, Sephadex G-lOO 
filtration, affinity chromatography on methotrexate- 
Sepharose and Sephadex G-25 filtration. The purified enzyme 
fraction was stable when kept frozen over several months.
It existed as a single electrophoretic form and with a 
molecular weight 19,600 t 3,000 as estimated by Sephadex 
G-lOO filtration.
About 2-3 fold increase in the catalytic activity of 
the hog thymus reductase was achieved by chaotropic agents, 
and the enzyme was inhibited by p-chloromercuribenzoate
-6 _ oover the concentration range 5 x 10" to 1 x 10"-̂  M. Double 
pH optima, one between pH 5*0 and 5*5 and another near pH
7.5 were observed. Higher enzyme activity was observed at 
the latter value. The presence of salts changed the pH- 
activity profile of dihydrofolate reductase.
FHg reductase from hog thymus was very sensitive to
Q
methotrexate. At pH 7.2, a drug concentration of 10” M was 
sufficient to cause greater than 50 % inhibition of enzyme
53
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activity. The degree of inhibition by this antifolate drug 
was dependent upon the pH, Binding of methotrexate to the 
enzyme was reversible.
The enzyme reaction follows a sequential mechanism. 
Competitive inhibition was observed for NADP with respect 
to NADPH, whereas noncompetitive inhibition was obtained 
for NADP with respect to FH^ according to Cleland*s method 
of analysis of the kinetic data. The Michaelis constant for 
NADPH was calculated to be 0.6 aiM  and a value of 0.8 yuM was 
obtained for PHg. A dissociation constant of 2.3 -uM for FH2 
was also determined.
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